Journal article
Serologic antibodies in relation to outcome in postoperative Crohn's disease
Amy L Hamilton, Michael A Kamm, Peter De Cruz, Emily K Wright, Fabiyola Selvaraj, Fred Princen, Alexandra Gorelik, Danny Liew, Ian C Lawrance, Jane M Andrews, Peter A Bampton, Miles P Sparrow, Timothy H Florin, Peter R Gibson, Henry Debinski, Richard B Gearry, Finlay A Macrae, Rupert W Leong, Ian Kronborg, Graham Radford-Smith Show all
Journal of gastroenterology and hepatology | WILEY | Published : 2017
DOI: 10.1111/jgh.13677
Abstract
BACKGROUND AND AIM: Disease recurs frequently after Crohn's disease resection. The role of serological antimicrobial antibodies in predicting recurrence or as a marker of recurrence has not been well defined. METHODS: A total of 169 patients (523 samples) were prospectively studied, with testing peri-operatively, and 6, 12 and 18 months postoperatively. Colonoscopy was performed at 18 months postoperatively. Serologic antibody presence (perinuclear anti-neutrophil cytoplasmic antibody [pANCA], anti-Saccharomyces cerevisiae antibodies [ASCA] IgA/IgG, anti-OmpC, anti-CBir1, anti-A4-Fla2, anti-Fla-X) and titer were tested. Quartile sum score (range 6-24), logistic regression analysis, and corre..
View full abstractGrants
Funding Acknowledgements
Prometheus Laboratories provided testing of the study samples. AbbVie, Gutsy Group, Gandel Philanthropy, Angior Foundation, and Crohn's Colitis Australia provided funding for the POCER study. The National Health and Medical Research Council (NHMRC) supported A. L. H., E. K. W., P. D. C., R. W. L., and M. A. K. We are grateful to colleagues and centers for their participation.